2025
Financial Volatility and Investment Dynamics in the Pharmaceutical Sector: Evidence from the Covid-19 Pandemic
KALAMEN, Kristián; František POLLÁK; Roman VAVREK; Petra PÁRTLOVÁ; Mónica GARCÍA-MELÓN et al.Basic information
Original name
Financial Volatility and Investment Dynamics in the Pharmaceutical Sector: Evidence from the Covid-19 Pandemic
Authors
KALAMEN, Kristián; František POLLÁK; Roman VAVREK; Petra PÁRTLOVÁ and Mónica GARCÍA-MELÓN
Edition
Polish Journal of Management Studies, 2025, 2081-7452
Other information
Language
English
Type of outcome
Article in a journal
Field of Study
50200 5.2 Economics and Business
Country of publisher
Poland
Confidentiality degree
is not subject to a state or trade secret
References:
Impact factor
Impact factor: 1.100 in 2024
Marked to be transferred to RIV
Yes
RIV identification code
RIV/75081431:_____/25:00002897
Organization unit
Institute of Technology and Business in České Budějovice
UT WoS
Keywords in English
pharmaceutical sector; covid-19; stock market volatility; investment risk; financial resilience
Tags
Changed: 25/7/2025 07:41, Ing. Barbora Langšádlová
Abstract
In the original language
This study aims to analyze the financial impact of the COVID-19 pandemic on the pharmaceutical sector by assessing market volatility, stock performance, and investment behavior across different pandemic waves. It provides a novel perspective by examining the different financial responses of major pharmaceutical companies, Johnson and Johnson, Pfizer, and Moderna, over 949 trading days (March 2019-December 2022). Using statistical tools such as standard deviation and kurtosis, the study identifies volatility patterns and extreme price movements before, during, and after the pandemic. The results show that the first and fourth waves had the highest market volatility, influenced by vaccine development, regulatory decisions and changing investor sentiment. While short-term financial gains were significant, long-term profitability was challenged by market corrections and policy constraints. This study contributes to the literature by providing insights into crisis-driven financial instability and highlights the need for risk aware investment strategies in the pharmaceutical sector.